AU2014239186B2 - Apolipoprotein mimetics and uses thereof - Google Patents

Apolipoprotein mimetics and uses thereof Download PDF

Info

Publication number
AU2014239186B2
AU2014239186B2 AU2014239186A AU2014239186A AU2014239186B2 AU 2014239186 B2 AU2014239186 B2 AU 2014239186B2 AU 2014239186 A AU2014239186 A AU 2014239186A AU 2014239186 A AU2014239186 A AU 2014239186A AU 2014239186 B2 AU2014239186 B2 AU 2014239186B2
Authority
AU
Australia
Prior art keywords
apo
mimetic
treatment cycle
seq
rest phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014239186A
Other languages
English (en)
Other versions
AU2014239186A1 (en
Inventor
G.M. Anantharamaiah
Dennis Goldberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
LipimetiX Development LLC
Original Assignee
UAB Research Foundation
LipimetiX Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation, LipimetiX Development LLC filed Critical UAB Research Foundation
Publication of AU2014239186A1 publication Critical patent/AU2014239186A1/en
Assigned to LIPIMETIX DEVELOPMENT, LLC, UAB RESEARCH FOUNDATION reassignment LIPIMETIX DEVELOPMENT, LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: UAB RESEARCH FOUNDATION
Application granted granted Critical
Publication of AU2014239186B2 publication Critical patent/AU2014239186B2/en
Priority to AU2017203911A priority Critical patent/AU2017203911B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2014239186A 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof Ceased AU2014239186B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017203911A AU2017203911B2 (en) 2013-03-14 2017-06-09 Apolipoprotein mimetics and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361782956P 2013-03-14 2013-03-14
US61/782,956 2013-03-14
US201361834992P 2013-06-14 2013-06-14
US61/834,992 2013-06-14
PCT/US2014/027719 WO2014152776A1 (en) 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017203911A Division AU2017203911B2 (en) 2013-03-14 2017-06-09 Apolipoprotein mimetics and uses thereof

Publications (2)

Publication Number Publication Date
AU2014239186A1 AU2014239186A1 (en) 2015-10-08
AU2014239186B2 true AU2014239186B2 (en) 2017-04-20

Family

ID=51581312

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014239186A Ceased AU2014239186B2 (en) 2013-03-14 2014-03-14 Apolipoprotein mimetics and uses thereof
AU2017203911A Ceased AU2017203911B2 (en) 2013-03-14 2017-06-09 Apolipoprotein mimetics and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017203911A Ceased AU2017203911B2 (en) 2013-03-14 2017-06-09 Apolipoprotein mimetics and uses thereof

Country Status (12)

Country Link
US (1) US20160002315A1 (enExample)
EP (1) EP2996706B1 (enExample)
JP (2) JP6570511B2 (enExample)
AU (2) AU2014239186B2 (enExample)
BR (1) BR112015022624A2 (enExample)
CA (1) CA2903869A1 (enExample)
DK (1) DK2996706T3 (enExample)
ES (1) ES2753381T3 (enExample)
IL (1) IL240787B (enExample)
MX (1) MX2015012818A (enExample)
NZ (1) NZ713291A (enExample)
WO (1) WO2014152776A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
WO2017120568A1 (en) * 2016-01-08 2017-07-13 Lipimetix Development, Inc. Apoe mimetic peptide compositions
IL260931B2 (en) * 2016-02-17 2024-09-01 Regeneron Pharma Methods of treating or preventing atherosclerosis by blocking ANGPTL3
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
US20240279313A1 (en) * 2021-08-11 2024-08-22 The Regents Of The University Of California Barrier function preserving peptides for membranes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286025A1 (en) * 2007-08-28 2010-11-11 Anantharamaiah Gattadahalli M Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20130005645A1 (en) * 2010-01-06 2013-01-03 Vitek Michael P Apoe peptide dimers and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
US5631280A (en) 1995-03-29 1997-05-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6506880B2 (en) 1998-03-17 2003-01-14 The Uab Research Foundation Synthetic peptides that enhance atherogenic lipoprotein uptake and lower plasma cholesterol
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
JP7081923B2 (ja) * 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100286025A1 (en) * 2007-08-28 2010-11-11 Anantharamaiah Gattadahalli M Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20130005645A1 (en) * 2010-01-06 2013-01-03 Vitek Michael P Apoe peptide dimers and uses thereof

Also Published As

Publication number Publication date
US20160002315A1 (en) 2016-01-07
EP2996706B1 (en) 2019-07-31
AU2017203911A1 (en) 2017-06-29
JP2019089834A (ja) 2019-06-13
JP2016515137A (ja) 2016-05-26
WO2014152776A1 (en) 2014-09-25
MX2015012818A (es) 2016-05-12
DK2996706T3 (da) 2019-10-21
EP2996706A4 (en) 2017-01-18
AU2014239186A1 (en) 2015-10-08
NZ713291A (en) 2017-04-28
EP2996706A1 (en) 2016-03-23
CA2903869A1 (en) 2014-09-25
AU2017203911B2 (en) 2019-03-07
IL240787A0 (en) 2015-10-29
JP6570511B2 (ja) 2019-09-04
IL240787B (en) 2019-07-31
JP6772317B2 (ja) 2020-10-21
BR112015022624A2 (pt) 2017-10-31
ES2753381T3 (es) 2020-04-08

Similar Documents

Publication Publication Date Title
USRE50320E1 (en) APOE mimetic peptides and higher potency to clear plasma cholesterol
US8048851B2 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
AU2017203911B2 (en) Apolipoprotein mimetics and uses thereof
AU2006242651B2 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CA2704729C (en) Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20080293639A1 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
IL185959A (en) Radio link protocol enhancements to reduce setup time for data calls
RU2448977C2 (ru) Обладающий способностью облегчать по меньшей мере один симптом воспалительного состояния пептид, содержащая его фармацевтическая композиция и способ лечения атеросклероза с их помощью
RU2532222C2 (ru) Миметики аполипопротеина а-i
HK1242718B (en) Apoe mimetic peptides and higher potency to clear plasma cholesterol
HK1242718A1 (en) Apoe mimetic peptides and higher potency to clear plasma cholesterol
HK1147696A (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired